798 related articles for article (PubMed ID: 33268824)
1. New therapeutics beyond amyloid-β and tau for the treatment of Alzheimer's disease.
Zhang F; Zhong RJ; Cheng C; Li S; Le WD
Acta Pharmacol Sin; 2021 Sep; 42(9):1382-1389. PubMed ID: 33268824
[TBL] [Abstract][Full Text] [Related]
2. Tryptamine: A privileged scaffold for the management of Alzheimer's disease.
Singh YP; Kumar H
Drug Dev Res; 2023 Dec; 84(8):1578-1594. PubMed ID: 37675624
[TBL] [Abstract][Full Text] [Related]
3. Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors.
Tayeb HO; Yang HD; Price BH; Tarazi FI
Pharmacol Ther; 2012 Apr; 134(1):8-25. PubMed ID: 22198801
[TBL] [Abstract][Full Text] [Related]
4. Patchouli alcohol attenuates the cognitive deficits in a transgenic mouse model of Alzheimer's disease via modulating neuropathology and gut microbiota through suppressing C/EBPβ/AEP pathway.
Xu QQ; Su ZR; Yang W; Zhong M; Xian YF; Lin ZX
J Neuroinflammation; 2023 Jan; 20(1):19. PubMed ID: 36717922
[TBL] [Abstract][Full Text] [Related]
5. 9R, the cholinesterase and amyloid beta aggregation dual inhibitor, as a multifunctional agent to improve cognitive deficit and neuropathology in the triple-transgenic Alzheimer's disease mouse model.
Ju Y; Tam KY
Neuropharmacology; 2020 Dec; 181():108354. PubMed ID: 33035533
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic strategies for Alzheimer's disease in clinical trials.
Godyń J; Jończyk J; Panek D; Malawska B
Pharmacol Rep; 2016 Feb; 68(1):127-38. PubMed ID: 26721364
[TBL] [Abstract][Full Text] [Related]
7. New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs.
Salomone S; Caraci F; Leggio GM; Fedotova J; Drago F
Br J Clin Pharmacol; 2012 Apr; 73(4):504-17. PubMed ID: 22035455
[TBL] [Abstract][Full Text] [Related]
8. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
Bond M; Rogers G; Peters J; Anderson R; Hoyle M; Miners A; Moxham T; Davis S; Thokala P; Wailoo A; Jeffreys M; Hyde C
Health Technol Assess; 2012; 16(21):1-470. PubMed ID: 22541366
[TBL] [Abstract][Full Text] [Related]
9. [Anti-dementia drugs for Alzheimer disease in present and future].
Nabeshima T; Noda Y; Kamei H
Nihon Yakurigaku Zasshi; 2002 Nov; 120(1):24P-29P. PubMed ID: 12491771
[TBL] [Abstract][Full Text] [Related]
10. Gut Microbiota Composition and Epigenetic Molecular Changes Connected to the Pathogenesis of Alzheimer's Disease.
Nagu P; Parashar A; Behl T; Mehta V
J Mol Neurosci; 2021 Jul; 71(7):1436-1455. PubMed ID: 33829390
[TBL] [Abstract][Full Text] [Related]
11. Alzheimer's disease: Molecular aspects and treatment opportunities using herbal drugs.
Thakral S; Yadav A; Singh V; Kumar M; Kumar P; Narang R; Sudhakar K; Verma A; Khalilullah H; Jaremko M; Emwas AH
Ageing Res Rev; 2023 Jul; 88():101960. PubMed ID: 37224884
[TBL] [Abstract][Full Text] [Related]
12. Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer's disease.
Ruthirakuhan M; Herrmann N; Suridjan I; Abraham EH; Farber I; Lanctôt KL
Expert Opin Pharmacother; 2016 Dec; 17(18):2417-2429. PubMed ID: 27825018
[TBL] [Abstract][Full Text] [Related]
13. Screening of treatment targets for Alzheimer's disease from the molecular mechanisms of impairment by β-amyloid aggregation and tau hyperphosphorylation.
Lin LF; Luo HM
Neurosci Bull; 2011 Feb; 27(1):53-60. PubMed ID: 21270904
[TBL] [Abstract][Full Text] [Related]
14. Toluidine blue O attenuates tau phosphorylation in N2a-APPSwe cells.
Onder S; Biberoglu K; Yuksel M; Tacal O
Chem Biol Interact; 2022 Oct; 366():110126. PubMed ID: 36027949
[TBL] [Abstract][Full Text] [Related]
15. Recent Developments in Tacrine-based Hybrids as a Therapeutic Option for Alzheimer's Disease.
Yamali C; Donmez S
Mini Rev Med Chem; 2023; 23(7):869-880. PubMed ID: 36464869
[TBL] [Abstract][Full Text] [Related]
16. An update on drug treatment options of Alzheimer's disease.
Allgaier M; Allgaier C
Front Biosci (Landmark Ed); 2014 Jun; 19(8):1345-54. PubMed ID: 24896354
[TBL] [Abstract][Full Text] [Related]
17. Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease.
Fisher A
Neurotherapeutics; 2008 Jul; 5(3):433-42. PubMed ID: 18625455
[TBL] [Abstract][Full Text] [Related]
18. A review on Alzheimer's disease pathophysiology and its management: an update.
Kumar A; Singh A; Ekavali
Pharmacol Rep; 2015 Apr; 67(2):195-203. PubMed ID: 25712639
[TBL] [Abstract][Full Text] [Related]
19. Role of tau protein in Alzheimer's disease: The prime pathological player.
Muralidar S; Ambi SV; Sekaran S; Thirumalai D; Palaniappan B
Int J Biol Macromol; 2020 Nov; 163():1599-1617. PubMed ID: 32784025
[TBL] [Abstract][Full Text] [Related]
20. Reducing Aβ load and tau phosphorylation: Emerging perspective for treating Alzheimer's disease.
Kalra J; Khan A
Eur J Pharmacol; 2015 Oct; 764():571-581. PubMed ID: 26209363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
